Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

By A. Adjei, R. Cohen, W. Franklin, C. Morris, David M. Wilson, J. Molina, L. Hanson, L. Gore, L. Chow, S. Leong and 10 more. Journal of Clinical Oncology, 2008

604 citations recorded by the source corpus.

Subfields: Molecular Biology, Ophthalmology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/39b99bfa8c0d3384411c8597d6fd518528c2ce04

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Wanding Zhou
2. P. Park
3. Hui Shen
4. Peter W. Laird
5. Elaine R. Mardis
6. Ilya Shmulevich
7. Niranjan Nagarajan
8. Katherine A. Hoadley

In Ophthalmology

1. Christopher Sander
2. Nikolaus Schultz

In Pulmonary and Respiratory Medicine

1. Mark A. Rubin
2. S. Lippman
3. Marc Ladanyi
4. J. Luketich
5. Christine Lovly
6. Z. Du
7. M. Davis

Citations in the corpus

• Targeting the Mitogen-Activated Protein Kinase RAS-RAF Signaling Pathway in Cancer Therapy (2012, background): “In this trial seven patients developed transient and reversible blurred vision, nine patients showed disease stabilization lasting for at least 5 months and a strong reduction in ERK1/2 phosphorylation (mean inhibition of 79%) in tumor biopsies [59].”
• V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway (2009, background): “Such agents are now in clinical trial and have antitumor activity in patients with melanoma (13, 14).”
• Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. (2010, background): “The vast majority of kinase inhibitor development is in the cancer field (128), and that is the case with ERK inhibitors (2, 281, 344).”
• Comprehensive Characterization of Cancer Driver Genes and Mutations (2018, background): “…are present in 8%of samples and could be sensitive to MEK inhibitors via repurposing; some NRAS mutations are sensitive in SKCM to MEK inhibition in clinical trials, particularly when combined with CDK4 inhibition (Adjei et al., 2008; Ascierto et al., 2013; Dummer et al., 2017; Iams et al., 2017).”